2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 531

Disease Activity and Physical Fatigue As Related to Adherence and Health Literacy in Patients with Rheumatoid Arthritis
Abstract Number: 1407

Disease Activity Trackers to Support Treat to Target Strategies: A Needs Assessment Survey
Abstract Number: 600

Disease Activity Trends after Dose Escalation of Infliximab (Remicade) – Results from United States Consortium of Rheumatology Researchers of North America Registry
Abstract Number: 1944

Disease Activity, Glucocorticoid Exposure, and Rituximab Determine Body Composition Changes during Induction Treatment of ANCA-Associated Vasculitis
Abstract Number: 585

Disease Associated Anti-Citrullinated Protein Memory B Cells in Rheumatoid Arthritis Persist in DAS Remission
Abstract Number: 1731

Disease Burden and Impact of Certolizumab Pegol Treatment on Workplace and Household Productivity Across Working Age Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis Patients
Abstract Number: 1522

Disease Burden in Rheumatoid Arthritis (RA) Patients Who Have Secondary Osteoarthritis (OA) Is Lower Than in OA but Higher Than in RA with No Secondary OA
Abstract Number: 1521

Disease Characteristics and Change of Arthritis Activity According to Treatment in Hepatitis B Surface Antigen Positive Rheumatoid Arthritis Patients
Abstract Number: 127

Disease Characteristics and Outcomes in African-American Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: a High Risk Group for Poor Outcomes
Abstract Number: 2976

Disease Flares and Persistent Low-Level of Disease: Long-Term Outcome in a Cohort of Patients with BehçEt’s Disease
Abstract Number: 1331

Disease Patterns and Long Term Outcome Amongst Patients with Relapsing Polychondritis – Single Centre Experience
Abstract Number: 1730

Disease Progression Among Non-Achievers of Minimal Disease Activity in Psa Patients Treated with Infliximab or Golimumab
Abstract Number: 298

Disease Progression in Osteoarthritis Is Driven By Multiple Disease Parameters Leading to Comparable Levels of Joint Destruction
Abstract Number: 248

Disease Severity and High Attack Frequency Under Colchicine Treatment Is Associated with Increased Carotid Intima Media Thickness in FMF
Abstract Number: 2112

Disease-Activity Associated Autoantibodies to Malondialdehyde-Modified Proteins Can be Isolated from Synovial B Cells in RA

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].